Chat with us, powered by LiveChat

Loading...

Radiodermatitis Market Report

RA01170

Radiodermatitis Market by Product (Topical, Oral, and Dressings), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2021–2028

RA01170

Pages: 169

Sep 2021

COVID-19

pandemic has shown to have an enormous impact on most
industries.

Click Here to access our comprehensive analysis of the

Impact of covid-19 on Radiodermatitis Market

Global Radiodermatitis Market Analysis

According to the global radiodermatitis market forecast, the market is expected to reach up to $561.7 million by 2028, surging from $412.4 million in 2020, at a noteworthy CAGR of 4.1%.

Market Synopsis

Massive rise in the adoption of radiotherapy is anticipated to fuel the growth of the global radiodermatitis market.

However, lower product penetration of radiodermatitis in the middle or low-income countries, may restrict the radiodermatitis market growth.

According to the regional analysis of the radiodermatitis market, the North America market is expected to surge at a CAGR of 5.4%, by registering a revenue of $155.0 million, throughout the analysis period.

Radiodermatitis Overview

Radiodermatitis (also known for radiation dermatitis) is a condition caused by the high-energy waves or particles, namely gamma rays, x-rays, protons, or electron beams delivered during radiation therapy. Radiation dermatitis affects almost 95% of the patients who receive radiation for the cancer treatment, with an around 85% of patients having moderate-to-severe cutaneous condition. The severity of the skin reactions ranges mainly from mild erythema to dry desquamation.s

Covid-19 Impact on Radiodermatitis Market

The corona virus pandemic has had significantly disrupted the growth of the industries worldwide, creating a mass disturbance for sellers as well as buyers. Moreover, the global pandemic has also impacted the global radiodermatitis industry in a negative way. Furthermore, multiple manufacturers namely BMG Pharma SPA and Convatec Group Plc in radiodermatitis faced challenges in supply of their products and witnessed declined growth in the market, during the analysis period.

However, in June 2020, leading cancer institutions such as the Italian Association of Radiotherapy and Clinical Oncology (AIRO) reported that radiotherapy has proven to be the safest and most appropriate cancer treatment, throughout the COVID-19 outbreak. Whereas radiodermatitis is a common side-effect of radiotherapy, which can cause the damage to skin cells of the patient. Hence, the demand for radiodermatitis products may foresee positive impact on the global market, post COVID-19 crisis.

Growing Prevalence of Cancer to Upsurge the Market Growth

Growth of global radiodermatitis market is driven by the significantly increasing prevalence of cancer worldwide. As per information published by World Health Organization (WHO), the specialized agency of the United Nations (UN) responsible for public health, cancer is a main cause of death around the globe, accounting for almost 10 million deaths in 2020. Also, in 2020, most common diseases were skin cancer (non-melanoma) (1.20 million cases) and breast cancer (2.26 million cases). Hence, the adoption of radiodermatitis treatment globally is expected to massively increase, which may eventually bolster the radiodermatitis industry, during the forecast period.

To know more about global radiodermatitis market drivers, get in touch with our analysts here.

Lower Product Penetration in the Low-Income Regions to Restrain the Market Growth

However, lack of information regarding the chronic and acute radiodermatitis across the pharmacies in middle or low-income countries may restrain the market growth of global radiodermatitis market, throughout the projected period. Further, high cost radiodermatitis products may also negatively impact the radiodermatitis market, in the coming years

Significant Expansion of Healthcare Establishments across the Asia-Pacific Region to Create Investment Opportunities

Asian countries such as India, Japan, China, and Singapore have experienced the notable expansion of biotechnology & pharmaceutical companies in the recent several years. Furthermore, the extensively increasing awareness among Asian consumers regarding enhancing the quality of life has also increased. In addition to this, burden of various chronic conditions including skin cancer and breast cancer is extremely increasing in the APAC region. Thereby the consumption and constant growth of radiodermatitis in this region has increased, which can create the market opportunities for global radiodermatitis industry, in the forecast period.

To know more about global radiodermatitis market opportunities, get in touch with our analysts here.

Radiodermatitis Market
By Product

Your browser does not support the canvas element.

Based on type, the market has been divided into Topical, oral, and dressings sub-segments of which the Topical sub-segment is anticipated to experience the fastest growth and hold the most dominant market share. Download Exclusive Sample Report

Source: Research Dive Analysis

The topical product sub-segment is projected to have the maximum share in the global market and is anticipated to register a revenue of $380.2 million, in the analysis period.The extensive growth in topical products is mainly attributed to its bioavailability, cost-effectiveness, and easier application. Further, owing to the presence of a broad range of topical products including topical antibiotics, corticosteroids, and hydrophilic creams as well as surge in the demand for modern wound care options are some of the major factors accelerating the sub-segment’s growth.

Radiodermatitis Market
By Distribution Channel

Your browser does not support the canvas element.

Based on distribution channel, the segment has been categorized into Hospital Pharmacy, retail pharmacy, and online pharmacy. Out of these, the online pharmacy sub-segment is predicted to have the fastest growth and Hospital Pharmacy sub-segment is anticipated to garner the maximum revenue share in the global market.

Source: Research Dive Analysis

The online pharmacy sub-segment of the global radiodermatitis market is predicted to have a rapid growth and surpass $148.3 million by 2028, with the rise from $103.2 million in 2020.Increasing adoption of online pharmacy in the radiodermatitis market may create favorable conditions for the investors worldwide. Online pharmacy is an excellent platform which is playing important role in the sales of radiodermatitis medicines. Online pharmacy enables customer to order radiodermatitis medicines in the convenient and hassle-free fashion, via computer or smartphone phone. Such value additions in the global radiodermatitis industry, may further create enormous opportunities, in the coming years.

The hospital pharmacy sub-segment is predicted to have a dominating market share in the global market and is anticipated to generate a revenue of $243.6 million, during the forecast period. The growth of hospital pharmacy sub-segment is mainly attributed to the elements such as strategic developments between prominent players and hospitals, along with dramatically increasing geriatric population. Hospital pharmacy sub-segment is considered to be the one of the most important healthcare infrastructures majorly because it provides enhanced outpatient services, combined with improved patient satisfaction. Hence, the demand for radiodermatitis medicines in the hospital pharmacy sub-segment is expected to grow substantially, which may further accelerate the market, in the forecasted years.

Global Radiodermatitis Market, Regional Insights:

The radiodermatitis market was investigated across North America, Europe, Asia-Pacific, and LAMEA.

Global Radiodermatitis Market, Regional Insights

Source: Research Dive Analysis

The Market for Radiodermatitis in North America to be the Fastest Growing

The North America radiodermatitis market accounted $102.7 million in 2020 and is anticipated to register a revenue of $155.0 million by 2028. North America is the rapidly growing region in the global radiodermatitis market and is expected to grow exponentially due to the increasing incidence of cancer-causing diseases. Moreover, the robust presence of Cardinal Health, 3M, and Mylan N.V. combined with their innovative product developments are further projected to positively impact the global radiodermatitis market, in the analysis period.

The Market for Radiodermatitis in Asia-Pacific to be the Most Dominant

The share of Asia-Pacific radiodermatitis market is anticipated to grow at a CAGR of 3.1%, by registering a revenue of $170.8 million by 2028. Asia-Pacific region held the massive radiodermatitis market share in 2020, majorly due to the increase in disposable income, surge in the prevalence of cancer cases, massive adoption of advanced healthcare products, and growth in expenditure on healthcare infrastructure. In addition to this, inclusion of radiodermatitis medicines in healthcare reimbursements, along with spike in demand for radiation therapy specifically in China, Japan, and India may drive the Asia-Pacific radiodermatitis market, in the coming years.

Competitive Scenario in the Global Radiodermatitis Market

Product launches and mergers & acquisitions are common strategies followed by major market players.

Competitive Scenario in the Global Radiodermatitis Market

Source: Research Dive Analysis

Some of the leading radiodermatitis market players are 3M Company, Mölnlycke, HARTMANN, KeraNetics, Inc, Smith & Nephew Plc, Charles River Laboratories, The Jackson Laboratory, Stratpharma, InterMed S.A, and AceTech.

Porter’s Five Forces Analysis for the Global Radiodermatitis Market:

  • Bargaining Power of Suppliers: The economic costs of switching from one supplier/distributor to another is very low. Also, the easy availability as well as lower cost raw materials are also decreasing the negotiation power of suppliers.
    Hence, the bargaining power of suppliers is low.
  • Bargaining Power of Buyers: Global radiodermatitis market has moderate number of customers which slightly reduces the negotiation power of buyers worldwide. Also, lower production cost, availability of multiple manufacturers, and unorganized radiodermatitis industry negatively affect the bargaining power of buyer. 
    Hence, the bargaining power of the buyers is moderate.
  • Threat of New Entrants: Companies entering the radiodermatitis market are implementing multiple effective strategies such as offering discounts and value propositions. 
    Hence, the threat of the new entrants is high.
  • Threat of Substitutes: There is no alternative product for radiodermatitis products.
    Thus, the threat of substitutes is low.
  • Competitive Rivalry in the Market: The competitive rivalry among industry leaders is rather intense, especially between the global players including 3M Company, Mölnlycke, and HARTMANN. These companies are launching their value-added services in the international market and strengthening the footprint worldwide. 
    Therefore, competitive rivalry in the market is high.

Aspect

Particulars

  Historical Market Estimations

  2019-2020

  Base Year for Market Estimation

  2020

  Forecast Timeline for Market Projection

  2021-2028

  Geographical Scope

 North America, Europe, Asia-Pacific, LAMEA

  Segmentation by Product

  • Topical
  • Oral
  • Dressings

  Segmentation by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

  Key Companies Profiled

  • 3M Company
  • Mölnlycke
  • HARTMANN
  • KeraNetics, Inc
  • Smith & Nephew Plc
  • Charles River Laboratories
  • The Jackson Laboratory
  • Stratpharma
  • InterMed S.A.
  • AceTech.

Frequently Asked Questions
 

A. The global radiodermatitis market size was over $412.4 million in 2020 and is projected to reach $561.7 million by 2028.

A. KeraNetics, Inc, Smith & Nephew Plc, and Charles River Laboratories are some of the key players in the global radiodermatitis market.

A. The North America region possesses great investment opportunities for investors to witness the most promising growth in the future.

A. North America radiodermatitis market is anticipated to grow at 5.4% CAGR during the forecast period.

A. Technological development and strategic partnerships are the key strategies opted by the operating companies in this market.

A. The Jackson Laboratory and Stratpharma are investing more on R&D activities for developing new products and technologies.

1.Research Methodology

1.1.Desk Research
1.2.Real time insights and validation
1.3.Forecast model
1.4.Assumptions and forecast parameters

1.4.1.Assumptions
1.4.2.Forecast parameters

1.5.Data sources

1.5.1.Primary
1.5.2.Secondary

2.Executive Summary

2.1.360° summary
2.2.By product trends
2.3.By distribution channel trends

3.Market overview

3.1.Market segmentation & definitions
3.2.Key takeaways

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five forces analysis

3.3.1.Bargaining power of consumers
3.3.2.Bargaining power of suppliers
3.3.3.Threat of new entrants
3.3.4.Threat of substitutes
3.3.5.Competitive rivalry in the market

3.4.Market dynamics

3.4.1.Drivers
3.4.2.Restraints
3.4.3.Opportunities

3.5.Technology landscape
3.6.Regulatory landscape
3.7.Patent landscape
3.8.Pricing overview

3.8.1.By Product
3.8.2.By Distribution channel

3.9.Market value chain analysis

3.9.1.Stress point analysis
3.9.2.Raw material analysis
3.9.3.Manufacturing process
3.9.4.Distribution channel analysis
3.9.5.Operating vendors

3.9.5.1.Raw material suppliers
3.9.5.2.Product manufacturers
3.9.5.3.Product distributors

3.10.Strategic overview

4.Radiodermatitis Market, by Product

4.1.Topical

4.1.1.Market size and forecast, by region, 2020-2028
4.1.2.Comparative market share analysis, 2020 & 2028

4.2.Oral Drugs

4.2.1.Market size and forecast, by region, 2020-2028
4.2.2.Comparative market share analysis, 2020 & 2028

4.3.Dressings

4.3.1.Market size and forecast, by region, 2020-2028
4.3.2.Comparative market share analysis, 2020 & 2028

5.Radiodermatitis Market, by Distribution channel

5.1.Hospital Pharmacy

5.1.1.Market size and forecast, by region, 2020-2028
5.1.2.Comparative market share analysis, 2020 & 2028

5.2.Retail Pharmacy

5.2.1.Market size and forecast, by region, 2020-2028
5.2.2.Comparative market share analysis, 2020 & 2028

5.3.Online Pharmacy

5.3.1.Market size and forecast, by region, 2020-2028
5.3.2.Comparative market share analysis, 2020 & 2028

6.Radiodermatitis Market, by Region

6.1.North America

6.1.1.Market size and forecast, by product, 2020-2028
6.1.2.Market size and forecast, by distribution channel, 2020-2028
6.1.3.Market size and forecast, by country, 2020-2028
6.1.4.Comparative market share analysis, 2020 & 2028

6.1.5.U.S.

6.1.5.1.Market size and forecast, by product, 2020-2028
6.1.5.2.Market size and forecast, by distribution channel, 2020-2028
6.1.5.3.Comparative market share analysis, 2020 & 2028

6.1.6.Canada

6.1.6.1.Market size and forecast, by product, 2020-2028
6.1.6.2.Market size and forecast, by distribution channel, 2020-2028
6.1.6.3.Comparative market share analysis, 2020 & 2028

6.1.7.Mexico

6.1.7.1.Market size and forecast, by product, 2020-2028
6.1.7.2.Market size and forecast, by distribution channel, 2020-2028
6.1.7.3.Comparative market share analysis, 2020 & 2028

6.2.Europe

6.2.1.Market size and forecast, by product, 2020-2028
6.2.2.Market size and forecast, by distribution channel, 2020-2028
6.2.3.Market size and forecast, by country, 2020-2028
6.2.4.Comparative market share analysis, 2020 & 2028

6.2.5.Germany 

6.2.5.1.Market size and forecast, by product, 2020-2028
6.2.5.2.Market size and forecast, by distribution channel, 2020-2028
6.2.5.3.Comparative market share analysis, 2020 & 2028

6.2.6.UK

6.2.6.1.Market size and forecast, by product, 2020-2028
6.2.6.2.Market size and forecast, by distribution channel, 2020-2028
6.2.6.3.Comparative market share analysis, 2020 & 2028

6.2.7.France

6.2.7.1.Market size and forecast, by product, 2020-2028
6.2.7.2.Market size and forecast, by distribution channel, 2020-2028
6.2.7.3.Comparative market share analysis, 2020 & 2028

6.2.8.Spain

6.2.8.1.Market size and forecast, by product, 2020-2028
6.2.8.2.Market size and forecast, by distribution channel, 2020-2028
6.2.8.3.Comparative market share analysis, 2020 & 2028

6.2.9.Italy 

6.2.9.1.Market size and forecast, by product, 2020-2028
6.2.9.2.Market size and forecast, by distribution channel, 2020-2028
6.2.9.3.Comparative market share analysis, 2020 & 2028

6.2.10.Rest of Europe

6.2.10.1.Market size and forecast, by product, 2020-2028
6.2.10.2.Market size and forecast, by distribution channel, 2020-2028
6.2.10.3.Comparative market share analysis, 2020 & 2028

6.3.Asia Pacific

6.3.1.Market size and forecast, by product, 2020-2028
6.3.2.Market size and forecast, by distribution channel, 2020-2028
6.3.3.Market size and forecast, by country, 2020-2028
6.3.4.Comparative market share analysis, 2020 & 2028

6.3.5.China

6.3.5.1.Market size and forecast, by product, 2020-2028
6.3.5.2.Market size and forecast, by distribution channel, 2020-2028
6.3.5.3.Comparative market share analysis, 2020 & 2028

6.3.6.India 

6.3.6.1.Market size and forecast, by product, 2020-2028
6.3.6.2.Market size and forecast, by distribution channel, 2020-2028
6.3.6.3.Comparative market share analysis, 2020 & 2028

6.3.7.Japan

6.3.7.1.Market size and forecast, by product, 2020-2028
6.3.7.2.Market size and forecast, by distribution channel, 2020-2028
6.3.7.3.Comparative market share analysis, 2020 & 2028

6.3.8.South Korea

6.3.8.1.Market size and forecast, by product, 2020-2028
6.3.8.2.Market size and forecast, by distribution channel, 2020-2028
6.3.8.3.Comparative market share analysis, 2020 & 2028

6.3.9.Australia

6.3.9.1.Market size and forecast, by product, 2020-2028
6.3.9.2.Market size and forecast, by distribution channel, 2020-2028
6.3.9.3.Comparative market share analysis, 2020 & 2028

6.3.10.Rest of Asia Pacific

6.3.10.1.Market size and forecast, by product, 2020-2028
6.3.10.2.Market size and forecast, by distribution channel, 2020-2028
6.3.10.3.Comparative market share analysis, 2020 & 2028

6.4.LAMEA

6.4.1.Market size and forecast, by product, 2020-2028
6.4.2.Market size and forecast, by distribution channel, 2020-2028
6.4.3.Market size and forecast, by country, 2020-2028
6.4.4.Comparative market share analysis, 2020 & 2028

6.4.5.Latin America  

6.4.5.1.Market size and forecast, by product, 2020-2028
6.4.5.2.Market size and forecast, by distribution channel, 2020-2028
6.4.5.3.Comparative market share analysis, 2020 & 2028

6.4.6.Middle East 

6.4.6.1.Market size and forecast, by product, 2020-2028
6.4.6.2.Market size and forecast, by distribution channel, 2020-2028
6.4.6.3.Comparative market share analysis, 2020 & 2028

6.4.7.Africa

6.4.7.1.Market size and forecast, by product, 2020-2028
6.4.7.2.Market size and forecast, by distribution channel, 2020-2028
6.4.7.3.Comparative market share analysis, 2020 & 2028

7.Company profiles

7.1.3M Company

7.1.1.Business overview
7.1.2.Financial performance
7.1.3.Product portfolio
7.1.4.Recent strategic moves & developments
7.1.5.SWOT analysis

7.2.Mölnlycke

7.2.1.Business overview
7.2.2.Financial performance
7.2.3.Product portfolio
7.2.4.Recent strategic moves & developments
7.2.5.SWOT analysis

7.3.HARTMANN

7.3.1.Business overview
7.3.2.Financial performance
7.3.3.Product portfolio
7.3.4.Recent strategic moves & developments
7.3.5.SWOT analysis

7.4.KeraNetics, Inc

7.4.1.Business overview
7.4.2.Financial performance
7.4.3.Product portfolio
7.4.4.Recent strategic moves & developments
7.4.5.SWOT analysis

7.5.Smith & Nephew Plc

7.5.1.Business overview
7.5.2.Financial performance
7.5.3.Product portfolio
7.5.4.Recent strategic moves & developments
7.5.5.SWOT analysis

7.6.Charles River Laboratories

7.6.1.Business overview
7.6.2.Financial performance
7.6.3.Product portfolio
7.6.4.Recent strategic moves & developments
7.6.5.SWOT analysis

7.7.The Jackson Laboratory

7.7.1.Business overview
7.7.2.Financial performance
7.7.3.Product portfolio
7.7.4.Recent strategic moves & developments
7.7.5.SWOT analysis

7.8.Stratpharma

7.8.1.Business overview
7.8.2.Financial performance
7.8.3.Product portfolio
7.8.4.Recent strategic moves & developments
7.8.5.SWOT analysis

7.9.InterMed S.A.

7.9.1.Business overview
7.9.2.Financial performance
7.9.3.Product portfolio
7.9.4.Recent strategic moves & developments
7.9.5.SWOT analysis

7.10.AceTech.

7.10.1.Business overview
7.10.2.Financial performance
7.10.3.Product portfolio
7.10.4.Recent strategic moves & developments
7.10.5.SWOT analysis

Radiodermatitis or radiation dermatitis is a condition caused by radiation therapy that is used for cancer treatment. This condition is caused by the high-energy waves or particles, namely x-rays, gamma rays, protons, or electron beams which are delivered during the radiation therapy. Radiodermatitis occurs in nearly 95% of the patients receiving radiation therapy, especially patients with head & neck cancer, breast cancer, skin cancer, sarcoma, or lung cancer. Radiodermatitis may be chronic or acute and includes localized erythema, hair loss (epilation), skin peeling (desquamation), necrosis, fibrosis, and other related conditions. The condition is usually treated with topical agents like topical antibiotics, corticosteroids, hydrophilic creams; oral medications such as oral analgesics, oral corticosteroids, antibiotics, and anti-inflammatory agents; and dressings.

COVID-19 Impact on Radiodermatitis Market

The outbreak of COVID-19 across the globe has adversely affected the global radiodermatitis market growth. Many manufacturers namely Convatec Group Plc and BMG Pharma SPA operating in the radiodermatitis market faced challenges in supply of their products due to lockdown restrictions imposed by various governments across the globe to curb the spread of the coronavirus. Besides, multiple hospitals around the globe decreased the radiotherapy treatment and focused on supporting the COVID-19 departments.

However, the leading cancer institutions such as the Italian Association of Radiotherapy & Clinical Oncology (AIRO), in June 2020 reported that radiotherapy has proven to be the most appropriate and the safest cancer treatment, throughout the COVID-19 outbreak. Radiodermatitis is a common side-effect of radiotherapy that can cause the damage to skin cells of the patient. Thus, the demand for radiodermatitis products may rise and progressively impact the global market, after the COVID-19 crisis.

Radiodermatitis Market Trends and Developments

The companies operating in the global industry are adopting several growth strategies and business tactics such as partnerships, collaboration, business expansion, and product launches to obtain a leading position in the global industry, which is predicted to drive the global radiodermatitis market growth in the upcoming years.

For instance, in April 2019, CIVCO Radiotherapy, the leading provider of innovative, high quality, patient-centric radiotherapy solutions, collaborated with Stratpharma AG, a Swiss company specializing in innovative topical medical products, to expand and focus on wound care in radiation therapy patients. The aim of both the companies is to focus on patient outcomes in the radiation therapy space.

In July 2020, AMERI Holdings, Inc., the US based IT service management company, announced that its proposed amalgamation partner, Jay Pharma Inc., an authorized distributor for some of the leading Indian & Multinational Pharmaceutical companies, may file 2 new investigational new drug (IND) applications for the treatment of radiodermatitis and glioblastoma multiforme (GBM).

In July 2020, KeraNetics Inc., the global leader in the manufacturing & development of purified keratin medical products, announced the addition of ‘KeraStat Cream’ to its KeraStat wound dressing portfolio. The KeraStat Cream has received the US Food & Drug Administration (FDA) approval for indications of radiation dermatitis. This product is especially designed by the company to reduce the skin damage and painful ulceration that occurs during the radiation therapy.

Forecast Analysis of Global Market

The global radiodermatitis market is projected to witness an exponential growth during the forecast period, owing to the rapid expansion of healthcare establishments in the Asian countries such as India, China, Japan, and Singapore in the recent several years. Conversely, the lack of awareness regarding the acute and chronic radiodermatitis across the pharmacies in the low- and middle- income countries is expected to hamper the market growth in the projected timeframe.

The growing prevalence of cancer along with the rising adoption of radiotherapy across the globe are the significant factors and radiodermatitis market trends estimated to bolster the growth of the global market in the coming future. According to a latest report published by Research Dive, the global radiodermatitis market is expected to garner $561.7 million during the forecast period (2021-2028). Regionally, the North America region is estimated to observe the fastest growth by 2028, owing to the presence of leading market players and the rising incidence of cancer-causing diseases in the region. The key players functioning in the global market include 3M Company, HARTMANN, Mölnlycke, KeraNetics, Inc., Charles River Laboratories, Smith & Nephew Plc., The Jackson Laboratory, InterMed S.A, Stratpharma, and AceTech.

Purchase Options

Personalize this research

  • Triangulate with your own data
  • Request your format and definition
  • Get a deeper dive on a specific application, geography, customer or competitor
10% Off on Customization
Contact Us

Customers Also Viewed